Loading viewer...
investor_presentation
Format: PDF investor_presentation
Commercial-stage biopharmaceutical company focused on developing novel cancer therapies through nuclear export inhibition. Presents pipeline progress for selinexor (XPOVIO) and eltanexor across multiple indications including multiple myeloma, endometrial cancer, and myelofibrosis, with cash runway into early 2024.
conference
80 Pages
investor_presentation
13 Pages
Huntsman Corporation
EnBW Energy 2024 Investor Presentation German Utility
investor_presentationinvestor_presentation
33 Pages
EnBW (Energie Baden-Württemberg)